A Study of Eloralintide (LY3841136) in Participants With Overweight or Obesity
Trial statusNot yet recruiting
Trial phasePhase 1
Trial typeInterventional
Biological sexAll
Age18-70
SponsorEli Lilly and Company
About this trial
The main purpose of the study is to measure and compare the effects of eloralintide and placebo on insulin sensitivity (how your body responds to insulin), metabolic health (things like sugar and cholesterol), and body weight in participants with obesity or overweight. For each participant, the study will last about 35 weeks and include 3 in patient visits totaling 7 days.
Eligibility criteria
Qualifiers
Have an hemoglobin A1c (HbA1c) value at screening of less than 6.5 percent (%).
Have a body mass index between 25 and 45 Kilogram per Square Meter (kg/m²).
Have had a stable body weight that has changed by less than 5% during the 3 months prior to screening.
Are individuals assigned male at birth (AMAB) or assigned female at birth (AFAB). Individuals of childbearing potential (IOCBP) and individuals not of childbearing potential (INOCBP) may participate in this study.
Disqualifiers
Have type 1 or type 2 diabetes mellitus, a history of ketoacidosis, or of hyperosmolar state or coma. Note: Participants with a history of gestational diabetes are eligible to participate in this study.
Have acute or chronic pancreatitis or a history of acute idiopathic pancreatitis.
Have a known clinically significant gastric emptying abnormality or chronically take drugs that directly affect gastrointestinal (GI) motility to a significant extent.
liposuction
Trial design
Treatments tested in this trial
- Eloralintide
- Placebo
Treatment groups
115 Participants
are divided into 2 treatment groupsLocations
1Profil Institut für Stoffwechselforschung41460, Neuss Germany
Sponsors and collaborators
Eli Lilly and Company
Lead sponsor
Source ClinicalTrials.gov